Sugi Predict

Sugi Predict / Compounds / SCHEMBL43728

SCHEMBL43728

SCHEMBL43728

CC(C)(C)OC(=O)N1CC[C@H](C(=O)O)C1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.62
▸ HSD17B10 Q99714 1/20 0.57
▸ RECQL P46063 1/20 0.55
▸ KMT2A Q03164 2/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ EPHX1 P07099 1/20 0.51
▸ PTPN2 P17706 1/20 0.50
▸ PTPN1 P18031 1/20 0.50
▸ PTPN6 P29350 1/20 0.50
▸ GPR119 Q8TDV5 1/20 0.48
▸ LMNA P02545 1/20 0.47
▸ USP30 Q70CQ3 3/20 0.47
▸ STS P08842 1/20 0.46
▸ ABL1 P00519 1/20 0.46
▸ RIN1 Q13671 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL42957 1.00 HPGD (0.62) HPGDHSD17B10RECQLKMT2AMEN1
SCHEMBL42958 1.00 HPGD (0.62) HPGDHSD17B10RECQLKMT2AMEN1
Hydrazine SCHEMBL28122436 0.97 HPGD (0.59) HPGDHSD17B10RECQLKMT2AMEN1
SCHEMBL27963722 0.91 HPGD (0.65) HPGDHSD17B10RECQLKMT2AMEN1
SCHEMBL40057 0.90 MEN1 (0.64) HPGDHSD17B10RECQLKMT2AMEN1
SCHEMBL40056 0.90 MEN1 (0.64) HPGDHSD17B10RECQLKMT2AMEN1
SCHEMBL181768 0.90 MEN1 (0.64) HPGDHSD17B10RECQLKMT2AMEN1
SCHEMBL18275033 0.89 HPGD (0.53) HPGDHSD17B10RECQLKMT2AMEN1
SCHEMBL43357 0.89 HPGD (0.66) HPGDHSD17B10RECQLKMT2AMAPT
SCHEMBL1439980 0.89 HPGD (0.61) HPGDHSD17B10RECQLKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 690 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747234-A1 KV1.3 POTASSIUM CHANNEL ANTAGONISTS Muna Therapeutics ApS (DK) 2026-05-27 — — EP disclosed
US-12637458-B2 Imidazo[1,2-a]pyridine compounds and their use in therapy IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2026-05-26 — — US disclosed
CN-119528901-B Thiazole compound, dessumo and/or deubiquitinase inhibitor, and preparation methods and applications thereof Shanghai tongji hospital (CN) 2026-05-26 — — CN disclosed
CN-122071469-A PARG inhibitor and preparation method and application thereof 烟台新药创制山东省实验室 2026-05-22 — — CN disclosed
US-12616682-B2 1-H-pyrrolo[2,3-c]pyridine compounds ACERTA PHARMA B.V. (NL) 2026-05-05 — — US disclosed
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof MBD Co., Ltd. (KR) 2026-04-28 — — US disclosed
US-20260109698-A1 MALT-1 MODULATORS EXSCIENTIA AI LIMITED (GB) 2026-04-23 — — US disclosed
EP-3565808-B1 COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS ARDELYX INC (US) 2026-03-04 — — EP disclosed
EP-4696316-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-18 — — EP disclosed
US-20260042740-A1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2026-02-12 — — US disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 — — US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 — — WO disclosed
WO-2006110884-A2 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS NEUROCRINE BIOSCIENCES, INC. (US) 2006-10-19 — — WO disclosed
WO-2006066896-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2006-06-29 — — WO disclosed
WO-2006040192-A1 PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS GLAXO GROUP LIMITED (GB) 2006-04-20 — — WO disclosed
EP-0703913-A1 IMIDAZOLE LIPOXYGENASE INHIBITORS PFIZER (US) 1996-04-03 — — EP disclosed
EP-0491943-A4 TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS RORER INT HOLDINGS (US) 1996-02-14 — — EP disclosed
WO-1994029299-A1 IMIDAZOLE LIPOXYGENASE INHIBITORS PFIZER INC. (US) 1994-12-22 — — WO disclosed
EP-0491943-A1 TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-07-01 — — EP disclosed
WO-1992000295-A1 TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042740-A1 RAS INHIBITORS KRAS, NRAS, HRAS HPGD 4089/4885HSD17B10 2950/4885RECQL 1560/4885
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof CYP4A11, CYP4B1, CYP4A22 HPGD 376/4885HSD17B10 65/4885RECQL 926/4885
US-12616682-B2 1-H-pyrrolo[2,3-c]pyridine compounds MEN1, PKD1, PKD2 HPGD 2427/4885HSD17B10 3811/4885RECQL 2122/4885
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 HPGD 2925/4885HSD17B10 1319/4885RECQL 4498/4885
US-12637458-B2 Imidazo[1,2-a]pyridine compounds and their use in therapy OGFR, CBR3, CBR1 HPGD 2803/4885HSD17B10 2865/4885RECQL 2612/4885
US-20260109698-A1 MALT-1 MODULATORS MALT1, BCL6, BCL3 HPGD 3569/4885HSD17B10 1966/4885RECQL 2588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.